ArticleFrontiers in immunology2025
Autonomic nervous system development-related signature as a novel predictive biomarker for immunotherapy in pan-cancers.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has revolutionized cancer treatment. However, its clinical application remains limited. There is an urgent need for new predictive and prognostic biomarkers that can identify more patients with objective and durable responses and thus, improve the accuracy of prognosis. Methods: A predictive model for immunotherapy was developed using 34 single-cell RNA sequencing (scRNA-Seq) datasets from various cancer types and eight bulk RNA-Seq datasets from immune checkpoint inhibitor (ICI) cohorts. Seven machine learning (ML) methods were applied to identify vital genes associated with both cancer and immune characteristics. Differentially expressed genes (DEGs) were validated using RT-PCR and immunohistochemical (IHC) analyses of clinical samples. Results: Analysis of scRNA-seq datasets and autonomic nervous system development (ANSD) scores revealed 20 genes comprising a novel ANSD-related differential signature (ANSDR.Sig). A pan-cancer predictive model for ICI prognosis based on ANSDR.Sig was constructed, with the random forest algorithm yielding the most robust performance. Further screening using five ML methods on the ICI RNA-seq datasets identified 18 key genes, forming the Hub-ANSDR.Sig. Regulatory network analysis revealed diversified molecular interactions between Hub-ANSDR.Sig genes, transcription factors, and miRNAs. Hub-ANSDR.Sig was strongly associated with immune cell infiltration, microsatellite instability (MSI), and overall survival (OS) across various cancer types. In gastric cancer (GC), its role in immune dysfunction, tumor mutational burden (TMB), MSI, mutation frequency, immune infiltration, cell-cell communication, and developmental trajectories was confirmed. Moreover, several Hub-ANSDR.Sig genes were differentially expressed in GC compared to normal tissue and were enriched in immunotherapy-sensitive GC samples relative to resistant ones. Conclusion: Our results offer novel insights into predicting immunotherapy efficacy using ANSD-related signature, with the goal of improving clinical strategies and expanding potential indications. This approach also aims to develop more accurate prediction models and therapeutic interventions, thereby helping more patients benefit from immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.